GEN Exclusives

More »

Wall Street BioBeat

More »
Apr 1, 2012 (Vol. 32, No. 7)

2012 Has the Makings of a Breakout Year

Clinical Data, Regulatory Decisions, and M&A Activity Fuel Positive Market Sentiment

  • Clinical Data and Regulatory Decisions to Impact Biotech Market Sentiment

    In a market environment of heightened volatility, regulatory decisions and pipeline successes or failures have a high potential to produce excessive stock price swing in a respective company’s stock, and may have collateral impact on companies in the same or related therapeutic area. A big focus will be on data coming out on Gilead/Pharmasset’s PSI-7977 for HCV. Other important data includes Biogen Idec’s Phase III readout for dexpramipexole for ALS, data from several of Celgene’s Apremilast trials, and Amgen’s complete Oncovex Phase III data in melanoma.

    Highly anticipated FDA decisions tend to be a source of high anxiety for investors. Key regulatory decisions that will demand the market’s attention include Vertex’ Kalydeco for cystic fibrosis, Ariad’s ridaforolimus for sarcoma, Ironwood’s linaclotide for irritable bowel syndrome, and Amarin’s AMR101 for patients with very high triglycerides.

    A theme that has been gaining momentum with investors is payors pushing back on prices of new therapies where there is no clear step forward over current treatments.

    Dendreon’s Provenge (for advanced prostate cancer) and Human Genome Sciences’ Benlysta (for the treatment of lupus) are examples where the demand for significant incremental efficacy to justify price may have impacted stock market valuations for these companies. However, developers of drugs that are seen as significant advancements in treatment are rewarded, such as the innovations in melanoma, hepatitis C, and atrial fibrillation.

  • Seeking Alternatives to a Tepid U.S. IPO Market

    While 2011 saw several biopharma IPO success stories—including NewLink Genetics and Clovis Oncology, both late-stage cancer companies with promising programs that priced late in the year—the number of biopharma IPOs priced in 2011 (seven) was down 46% from 2010.

    The appetite for risk taking in IPOs continued to be low, with a focus on de-risked stories in Phase III development or those with marketed products. Heightened market volatility in 2H11 contributed to this muted activity.

    A challenging global economic environment is prompting some companies and investors to explore additional financing and public listing options, including alternatives to the traditional U.S. IPO.

    U.S. based GI Dynamics, a developer of non-surgical approaches for treating type 2 diabetes and obesity, successfully completed an IPO in Australia during the summer of 2011 and now trades on the Australian Securities Exchange (ASX).

    Trimel Pharmaceuticals listed on the Toronto Stock Exchange and completed a concurrent private placement through a reverse merger with a capital pool company, a commonly used method of going public in Canada utilizing a clean public shell company created for the purpose of identifying and merging with a promising private company.

    Options to list on the ASX through reverse merger also exist and these reverse merger options, in both Australia and Canada, can be quicker that the traditional IPO route, often taking about three or four months to complete.

    Several private companies attempted reverse mergers with public companies traded on major U.S. exchanges. But, the U.S. reverse merger process can take significantly longer to complete, sometimes taking nine months or more.

    Synageva BioPharma, a clinical-stage biopharmaceutical company focused on treatments for rare diseases, successfully completed a reverse merger with Trimeris and traded up nearly 50% in its first month of trading. However, Allozyme could not consummate its proposed merger with Poniard Pharmaceuticals, indicating the common stock of the company resulting from the proposed merger would not qualify for listing on the Nasdaq Capital Market.

    Although changing, public perception of reverse mergers into public shells can be negative as investors weigh the fear of the “pump and dump” scenario against success stories like Cougar Biotechnology, acquired by J&J for over $1 billion.

  • Decisive Actions Will Garner the Greatest Rewards

    By now, we all know that the Eurozone debt crisis and U.S. election-year politics may fuel volatility in financial markets. Those companies that take decisive action when presented with pockets of opportunity to strengthen balance sheets or to consummate strategic deals will be better positioned to develop promising therapies for patients and to create value for shareholders.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?